Product News from the 10/07/05 News Brief

Share this article:

Pfizer received FDA approval to market Aromasin (exemestane tablets) for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two-to-three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy.

Abbott received FDA approval to market Humira (adalimumab) for first-line treatment of recent onset moderate to severe rheumatoid arthritis (RA). In 2002, Humira was approved to treat patients with moderately to severely active RA, who have had insufficient response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

Berlex, a U.S. affiliate of Schering AG, Germany, announced that the FDA has approved Angeliq (drospirenone and estradiol) to treat moderate to severe vasomotor symptoms associated with menopause. Belex said Angeliq will be the only hormone therapy to contain the unique progestin, drospirenone.

Share this article:

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.